Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“upstream regulators of RB have been involved in cancer initiation in patients, both in familial and sporadic cases, and in several organs and tissues25–27.”
From Cellular mechanisms of tumour suppression by the retinoblastoma gene (2008) · cites this paper as [26]
Citations
Cites
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966
Sherr, C. J. (1993) · Cell · doi:10.1016/0092-8674(93)90636-5 · Cited by 1,960
pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest
Hannon, G. J., & Beach, D. (1994) · Nature · doi:10.1038/371257a0 · Cited by 1,950
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P., & Wells, S. A. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.851 · Cited by 1,303
A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154
Hofstra, R. M. W., Landsvater, R. M., Ceccherini, I., Stulp, R. P., Stelwagen, T., Luo, Y., Pasini, B., Hoppener, J. W. M., van Amstel, H. K. P., Romeo, G., et al. (1994) · Nature · doi:10.1038/367375a0 · Cited by 1,149
Germline p16 mutations in familial melanoma
Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A. T., Ally, D. S., Sheahan, M. D., Clark, W. H., Tucker, M. A., & Dracopoli, N. C. (1994) · Nature Genetics · doi:10.1038/ng0994-15 · Cited by 977
Self-citationAnalysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus
Kamb, A., Shattuck-Eidens, D., Eeles, R., Liu, Q., Gruis, N. A., Ding, W., Hussey, C., Tran, T., Miki, Y., Weaver-Feldhaus, J., et al. (1994) · Nature Genetics · doi:10.1038/ng0994-22 · Cited by 855
Guan, K. L., Jenkins, C. W., Li, Y., Nichols, M. A., Wu, X., O'Keefe, C. L., Matera, A. G., & Xiong, Y. (1994) · Genes & Development · doi:10.1101/gad.8.24.2939 · Cited by 714
Research works printed but not linked: 1
- Walker, G.J. et al. .Mutations of the CDKN2/ p16INK4 gene in Australian melanoma kindreds. Hum. Molec. Genet. 4, 1845–1852 (1995).
Cited by
Items 401–500 of 817
Familial Melanoma; CDKN2A and Beyond
Gruis, N. A., van der Velden, P. A., Bergman, W., & Frants, R. R. (1999) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1038/sj.jidsp.5640181 · Cited by 28
“The generated fusion protein shows no binding capacity to CDK4 or CDK6 (Dr. G. Peters, personal communication).”
BackgroundInfluentialPrediction of Melanoma Risk in a Southern European Population Based on a Weighted Genetic Risk Score
Kypreou, K. P., Stefanaki, I., Antonopoulou, K., Karagianni, F., Ntritsos, G., Zaras, A., Nikolaou, V. A., Kalfa, I., Chasapi, V., Polydorou, D., et al. (2015) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2015.12.007 · Cited by 27
“, 1994), CDK4 (Puntervoll et al., 2013; Soufir et al., 1998; Zuo et al., 1996), and the recently described genes BAP1, MITF, TERT, POT1 and other shelterin complex genes (ACD and TERF2IP) (Aoude et al.”
BackgroundKittler, H., & Tschandl, P. (2013) · Dermatologic Clinics · doi:10.1016/j.det.2013.06.009 · Cited by 25
Molecular Bases of Cutaneous and Uveal Melanomas
Gaudi, S., & Messina, J. L. (2011) · Pathology Research International · doi:10.4061/2011/159421 · Cited by 25
Altered TERT promoter and other genomic regulatory elements: occurrence and impact
Heidenreich, B., & Kumar, R. (2017) · International Journal of Cancer · doi:10.1002/ijc.30735 · Cited by 27
The MeLiM Minipig: An Original Spontaneous Model to Explore Cutaneous Melanoma Genetic Basis
Bourneuf, E. (2017) · Frontiers in Genetics · doi:10.3389/fgene.2017.00146 · Cited by 26
“The CDK4 R24C activating mutation is also highly penetrant, although it concerns only a few families worldwide (Zuo et al., 1996; Soufir et al., 1998): this non-synonymous substitution changes an amino acid essential for binding of CDK4 to p16INK4A, leading to an increased proliferation.”
BackgroundWei, E. X., Li, X., & Nan, H. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.04.044 · Cited by 28
E‐cadherin and β‐catenin expression patterns in malignant melanoma assessed by image analysis
Pećina‐Šlaus, N., Martina, Ž., Kuŝec, V., Martić, T. N., Čačić, M., & Šlaus, M. (2006) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.2006.00601.x · Cited by 27
“Main candidates responsible for melanoma development and progression are CDKN2A and CDK4 genes residing on chromosomes 9p21 and 12q14, as well as MC1R gene located at 16q24.(11,12) These genes together with signal transduction pathways in which they are implied are primarily changed in hereditary melanoma.”
BackgroundSmits, R., Hofland, N., Edelmann, W., Geugien, M., Jagmohan-Changur, S., Albuquerque, C., Breukel, C., Kucherlapati, R., Kielman, M. F., & Fodde, R. (2000) · Genes, Chromosomes and Cancer · doi:10.1002/1098-2264(2000)9999:9999<::aid-gcc1033>3.0.co;2-r · Cited by 91
Islam, R., Rahaman, M. M., Hoque, H., Hasan, M. N., Prodhan, S. H., Ruhama, A., & Jewel, N. A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259691 · Cited by 26
CDK4 Inhibitors an Emerging Strategy for the Treatment of Melanoma
Lee, B., & McArthur, G. A. (2015) · Melanoma Management · doi:10.2217/mmt.15.14 · Cited by 27
Risks of Melanoma and Other Cancers in Melanoma-Prone Families over 4 Decades
Tucker, M. A., Elder, D. E., Curry, M., Fraser, M. C., Pichler, V., Zametkin, D. P., Yang, X. R., & Goldstein, A. M. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.01.021 · Cited by 25
Self-citationAlterations of the P16 gene in uterine cervical carcinoma from Indian patients
(bhar), A. T., Banerjee, S., Roy, A. K., Roychowdhury, S., & Panda, C. K. (2003) · International Journal of Gynecological Cancer · doi:10.1046/j.1525-1438.2003.13330.x · Cited by 24
Lack of germline CDK6 mutations in familial melanoma
Shennan, M. G., Badin, A.-C., Walsh, S. R., Summers, A. M., From, L., McKenzie, M. A., Goldstein, A. M., Tucker, M. A., Hogg, D., & Lassam, N. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203507 · Cited by 26
Self-citationAssociation Between Endothelin Receptor B Nonsynonymous Variants and Melanoma Risk
Soufir, N., Meziani, R., Lacapère, J.-J., Bertrand, G., Fumeron, F., Bourillon, A., Gérard, B., Descamps, V., Crickx, B., Ollivaud, L., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji253 · Cited by 30
No Evidence for BRAF as a Melanoma/Nevus Susceptibility Gene
Jackson, S., Harland, M., Turner, F., Taylor, C., Chambers, P. A., Randerson‐Moor, J. A., Swerdlow, A. J., dos‐Santos‐Silva, I., Beswick, S., Bishop, D. T., et al. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-04-0568 · Cited by 29
“1), CDK4 (2), and CDKN2A (p14ARF; refs.”
Quint, K. D., Rhee, J., Gruis, N. A., ter Huurne, J., Wolterbeek, R., van der Stoep, N., Bergman, W., & Kukutsch, N. A. (2012) · Acta Dermato Venereologica · doi:10.2340/00015555-1457 · Cited by 26
Xu, K., Mao, X., Mehta, M., Cui, J., Zhang, C., & Xu, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030750 · Cited by 24
“A number of genes or their mutations have been found to be associated with the development of melanoma such as MC1R [7], CDK4 [8] and CDKN2A [9].”
BackgroundCutaneous melanoma: family screening and genetic testing
Niendorf, K. B., & Tsao, H. (2006) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2005.00050.x · Cited by 23
The inherited susceptibility to cancer
Guilford, P. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000721 · Cited by 28
Mouse Models of Cell Cycle Regulators: New Paradigms
Aleem, E. A., & Kaldis, P. (2006) · Springer eBooks · doi:10.1007/400_023 · Cited by 25
Sargen, M. R., Calista, D., Elder, D. E., Massi, D., Chu, E. Y., Potrony, M., Pfeiffer, R. M., Carrera, C., Aguilera, P., Alós, L., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.03.100 · Cited by 25
Self-citationMolecular Characterization of Melanoma Cases in Denmark Suspected of Genetic Predisposition
Wadt, K., Aoude, L. G., Krogh, L., Sunde, L., Bojesen, A., Grønskov, K., Nine, W., Ek, J., Morten, T.-A., Andersen, M. K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122662 · Cited by 25
“Other high-risk melanoma genes have been discovered: cyclin-dependent kinase 4 (CDK4) [11], BRCA-1 associated protein (BAP1) [12], and recently via exome sequencing of dense melanoma families, several new high-risk genes affecting telomere functions have been identified: POT1, ACD, TERF2IP and TERT [13–16].”
BackgroundSelf-citationp16 INK 4a deficiency promotes DNA hyper‐replication and genetic instability in melanocytes
Fung, C., Pupo, G. M., Scolyer, R. A., Kefford, R. F., & Rizos, H. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12062 · Cited by 24
“This mutation has been iden- tified in the germline of patients predisposed to melanoma and renders CDK4 insensitive to p16INK4a inhibition (Wolfel et al., 1995; Zuo et al., 1996).”
BackgroundLorenzo, S. D., Fanale, D., Corradino, B., Calò, V., Rinaldi, G., Bazan, V., Giordano, A., Cordova, A., & Russo, A. D. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1108494 · Cited by 26
“E2F activates the transcription of S-phase genes, thereby promoting cell proliferation.(23) Moreover, Rane et al.”
BackgroundStolařová, L., Jelínková, S., Storchova, R., Macháčková, E., Zemánková, P., Vočka, M., Kodet, O., Král, J., Černá, M., Volkova, Z., et al. (2020) · Biomedicines · doi:10.3390/biomedicines8100404 · Cited by 22
“Germline CDK4 mutations cluster in exon 2, coding for a domain interacting with p16INK4 [12].”
BackgroundHyter, S. D., Bajaj, G., Liang, X., Barbacid, M., Ganguli‐Indra, G., & Indra, A. K. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00732.x · Cited by 22
“Loss of keratinocytic RXRa in cooperation with activated Cdk4 leads to larger melanocytic tumors in mice Involvement of the p16 ⁄ CDK4 pathway has been implicated in melanomagenesis in humans (Curtin et al., 2005; Kamb et al., 1994; Wolfel et al., 1995; Zuo et al., 1996).”
BackgroundInfluentialCooperativity ofCdk4R24CandRasin melanoma development
Chawla, R., Procknow, J. A., Tantravahi, R. V., Khurana, J., Litvin, J., & Reddy, E. P. (2010) · Cell Cycle · doi:10.4161/cc.9.16.12632 · Cited by 24
“Mutations of the Cdkn2a and Cdk4 genes are often observed in human familial melanoma.(2,3) Approximately 20–40% of familial melanoma patients inherit Cdkn2a mutations.”
Backgroundde Araújo, É. S. S., Pramio, D. T., Kashiwabara, A. Y., Pennacchi, P. C., Maria–Engler, S. S., Achatz, M. I., Campos, A. H. J. F. M., Neto, J. P. D., Rosenberg, C., Carraro, D. M., et al. (2015) · BioMed Research International · doi:10.1155/2015/376423 · Cited by 22
“Beta-values were retrieved for all CpG probes mapped within DNA sequences associated with the BAP1, CDK4, CDKN2A, KIT,MC1R, MGMT,MITF, PALB2, POT1, TERT, TNF, and TNFRSF10C genes (see Supplementary Tables 1 and 2 in Supplementary Material available online at http://dx.doi.org/10.1155/2015/376423).”
BackgroundInfluentialEvolution of approaches to identify melanoma missing heritability
Dalmasso, B., & Ghiorzo, P. (2020) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1738221 · Cited by 21
“CDK4 as a rare melanoma-predisposition gene [13,14], whose pathogenic variants have only been reported in”
BackgroundAshton‐Prolla, P., Bakos, L., Junqueira, G., Giugliani, R., Azevedo, S. J., & Hogg, D. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701030 · Cited by 25
“In addition, each patient was screened for the CDK4 mutations R24H and R24C (Zuo et al., 1996), and for splice variants in the p14 gene (Harland et al.”
BackgroundHonda, S., Tanaka, C., Yamada, S., Sano, T., Matsumoto, T., Itakura, M., & Yoshimoto, K. (2003) · Endocrine Journal · doi:10.1507/endocrj.50.309 · Cited by 22
Vax, V., Bibi, R., Díaz‐Cano, S. J., Gueorguiev, M., Kola, B., Borboli, N., Paillerets, B. B., Walker, G. J., Dedov, Grossman, A. B., et al. (2003) · Journal of Endocrinology · doi:10.1677/joe.0.1780301 · Cited by 22
“Rb is a tumour suppressor protein which controls the G1-S transition partly by blocking the activity of a group of transcription factors, E2F ( Zhang et al. 1999, Malumbres & Barbacid 2001).”
BackgroundMethodSelf-citationLack of germ-line mutations of CDK4, p16(INK4A), and p15(INK4B) in families with glioma.
Gao, L., Liu, L., van Meyel, D. J., Cairncross, G. J., Forsyth, P. A., Kimmel, D. W., Jenkins, R. B., Lassam, N. J., & Hogg, D. (1997) · PubMed · Cited by 21
The Genes and Genetics of Malignant Melanoma
Gibbs, P., Brady, B., & Robinson, W. A. (2002) · Journal of Cutaneous Medicine and Surgery · doi:10.1007/s10227-001-0037-6 · Cited by 24
A French CDK4-positive melanoma family with a co-inherited EDNRB mutation
Soufir, N., Ollivaud, L., Bertrand, G., Lacapère, J.-J., Descamps, V., Vitoux, D., Lebbé, C., Wolkenstein, P., Dupin, N., Saïag, P., et al. (2007) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2006.11.016 · Cited by 21
Docking-Dependent Regulation of the Rb Tumor Suppressor Protein by Cdk4
Wallace, M., & Ball, K. L. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.12.5606-5619.2004 · Cited by 29
“Similarly, expression of Rb(1-886) in the Rb null CDK-deficient cell line Saos2, together with cyclin D1 and Cdk4, gave no pronounced change in mobility (Fig.”
BackgroundMethodInfluentialThe p.G23S CDKN2A founder mutation in high-risk melanoma families from Central Italy
Gensini, F., Sestini, R., Piazzini, M., Vignoli, M., Chiarugi, A., Brandani, P., Ghiorzo, P., Salvini, C., Borgognoni, L., Palli, D., et al. (2007) · Melanoma Research · doi:10.1097/cmr.0b013e3282f1d328 · Cited by 22
Human kinome drug discovery and the emerging importance of atypical allosteric inhibitors
Eglen, R. M., & Reisine, T. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441003636820 · Cited by 24
“Cyclins are allosteric protein modulators that bind to sites outside of the catalytic domain of CDKs to alter conformation allowing enzyme activation [45].”
BackgroundInfluentialIncreased angiogenesis in Cdk4 R24C/R24C :Apc +/Min intestinal tumors
Abedin, Z. R., Ma, Z., & Reddy, E. P. (2010) · Cell Cycle · doi:10.4161/cc.9.12.12055 · Cited by 32
“Furthermore, the R24C mutation in Cdk4, which confers resistance to p16, has been associated with familial melanoma.(7,8) It has also been demonstrated that mice that are homozygous Cyclin dependent kinase 4 (Cdk4) is a cell cycle regulator involved in early G1 cell cycle progression and has been indirectly implicated…”
BackgroundInfluentialConditional transformation of rat embryo fibroblast cells by a cyclin D1-cdk4 fusion gene
Rao, R. N., Stamm, N. B., Otto, K. A., Kovacevic, S., Watkins, S. A., Rutherford, P., Lemke, S., Cocke, K., Beckmann, R. P., Houck, K. A., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1203009 · Cited by 19
“As a control, we introduced Y17F (Terada et al., 1995) and R24C mutations (Wolfel et al., 1995; Zuo et al., 1996) in cdk4, that are not known to inactivate cdk4, and assayed enzymatic activity of the fusion protein.”
BackgroundCDKN2A/CDK4 molecular study on 155 Italian subjects with familial and/or primary multiple melanoma
Majore, S., Simone, P. D., Crisi, A., Eibenschutz, L., Binni, F., Antigoni, I., Bernardo, C. D., Catricalà, C., & Grammatico, P. (2008) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2008.00446.x · Cited by 22
“Mutations of CDK4 seem to be a rare cause of melanoma susceptibility (Goldstein et al., 2002) and to date only seven families: two American, two French, one Norwegian, one Australian and one English have been described (Molven et al., 2005; Soufir et al., 1998, 2007; Zuo et al.,1996).”
BackgroundHypermutability of UV-treated plasmids in dysplastic nevus/familial melanoma cell lines.
Moriwaki, S. I., Tarone, R. E., Tucker, M. A., Goldstein, A. M., & Kraemer, K. H. (1997) · PubMed · Cited by 21
Self-citationGenetic Testing for Melanoma Predisposition: Current Challenges
Gerstenblith, M. R., Goldstein, A. M., Tucker, M. A., & Fraser, M. C. (2007) · Cancer Nursing · doi:10.1097/01.ncc.0000300165.98391.e7 · Cited by 20
Self-citationHereditary Genodermatoses with Cancer Predisposition
Gerstenblith, M. R., Goldstein, A. M., & Tucker, M. A. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.06.003 · Cited by 20
Self-citationContribution of genetic factors for melanoma susceptibility in sporadic US melanoma patients
Gardner, J. M., Helms, C., Liu, Y., Cornelius, L. A., & Bowcock, A. M. (2009) · Experimental Dermatology · doi:10.1111/j.1600-0625.2008.00807.x · Cited by 21
Malignant Melanoma–a Genetic Overview
Bloethner, S., Scherer, D., Drechsel, M., Hemminki, K., & Kumar, R. (2009) · Actas Dermo-Sifiliográficas · doi:10.1016/s0001-7310(09)73167-9 · Cited by 23
The genetics of melanoma: the UK experience
Newton‐Bishop, J., HARLAND, & Bishop, D. T. (1998) · Clinical and Experimental Dermatology · doi:10.1046/j.1365-2230.1998.00344.x · Cited by 19
“These families all share the same 19 base pair deletion in the CDKN2 gene which co-segregates with the cases.17 Further persuasive evidence also comes from functional studies of the p16 protein produced from CDKN2 mutations, in which functional impairment of the ability of p16 to bind to another protein, CDK4, has bee…”
BackgroundThe genetics of human skin diseases
Epstein, E. H. (1996) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(96)80005-0 · Cited by 19
Lang, J., Boxer, M., & Mackie, R. M. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06846.x · Cited by 19
Re: Association Between Endothelin Receptor B Nonsynonymous Variants and Melanoma Risk
Thirumaran, R. K., Thoelke, A., Ugurel, S., Hemminki, K., Schadendorf, D., & Kumar, R. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj336 · Cited by 19
Genotyping of cutaneous melanoma.
Glitza, I. C., & Davies, M. A. (2014) · PubMed · doi:10.3978/j.issn.2304-3865.2014.03.01 · Cited by 22
“the most common germline aberration in families without CDKN2A mutations (98).”
BackgroundBlood DNA methylation, nevi number, and the risk of melanoma
Pergoli, L., Favero, C., Pfeiffer, R. M., Tarantini, L., Calista, D., Cavalleri, T., Angelici, L., Consonni, D., Bertazzi, P. A., Pesatori, A. C., et al. (2014) · Melanoma Research · doi:10.1097/cmr.0000000000000112 · Cited by 20
Germline Variants in the POT1-Gene in High-Risk Melanoma Patients in Austria
Müller, C., Krunic, M., Wendt, J., von Haeseler, A., & Okamoto, I. (2018) · G3 Genes Genomes Genetics · doi:10.1534/g3.117.300394 · Cited by 17
“Melanoma associated mutations in cyclin-dependent kinase 4 (CDK4), which were also classified as high penetrance mutations, seem to be very rare as only a few families were reported since the initial report in 1996 (ZUO et al. 1996).”
BackgroundManagement of Familial Melanoma and Nonmelanoma Skin Cancer Syndromes
Santillan, A. A., Cherpelis, B. S., Glass, L. F., & Sondak, V. K. (2008) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2008.08.003 · Cited by 18
Thomas, J. W., Lee-Lin, S.-Q., & Green, E. D. (1999) · Mammalian Genome · doi:10.1007/s003359901088 · Cited by 18
“(b) A schematic representation of the genomic structure of human CDK4 is depicted, as reported by Zuo et al. (1996).”
BackgroundInfluentialRisk factors for the development of primary cutaneous malignant melanoma
MacKie, R. M. (2002) · Dermatologic Clinics · doi:10.1016/s0733-8635(02)00028-1 · Cited by 19
“The second gene defect identified in melanoma families is a mutation in the CDK4 gene found on chromosome 12 [5,6].”
BackgroundFamilial malignant melanoma ‐ overview
Dębniak, T. (2004) · Hereditary Cancer in Clinical Practice · doi:10.1186/1897-4287-2-3-123 · Cited by 17
“Up to now germline CDK4 mutations have been found in 3 families world-wide [36, 53, 54].”
BackgroundBahn, Y. J., Yadav, H., Piaggi, P., Abel, B. S., Gavrilova, O., Springer, D., Papazoglou, I., Zerfas, P. M., Skarulis, M. C., McPherron, A. C., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci162479 · Cited by 22
“This mutation renders the Cdk4 R24C kinase insensitive to inhibition by p16 Ink4a — a product of the CDKN2A locus (39, 40).”
Veinalde, R., Ozola, A., Azarjana, K., Molven, A., Akslen, L. A., Doniņa, S., Proboka, G., Čēma, I., Baginskis, A., & Pjanova, D. (2013) · Melanoma Research · doi:10.1097/cmr.0b013e3283608695 · Cited by 17
Influence of loss of function MC1R variants in genetic susceptibility of familial melanoma in Spain
de Torre‐Minguela, C., García‐Casado, Z., Martínez‐Escribano, J., Estrada, R. B., Bañuls, J., Oliver, V., Mercader, P., Defez, J. M. A., Frias, J., & Nagore, E. (2010) · Melanoma Research · doi:10.1097/cmr.0b013e32833b159d · Cited by 17
Reddy, H. K. D. L., Graña, X., Dhanasekaran, D. N., Litvin, J., & Reddy, E. P. (2010) · Genes & Cancer · doi:10.1177/1947601909358105 · Cited by 27
“Mutation of residue 24 from an Arg to Cys in Cdk4 occurs in familial cases of melanomas and confers resistance of the protein to inhibition by INK4 family members.(10,11) Mouse modeling experiments have shown that mice harboring a knock-in cdk4R24C mutation develop tumors at an accelerated rate.”
BackgroundChen, Z., Tao, Z., Chen, S., Chen, C., Li, F., & Xiao, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082288 · Cited by 18
“Alterations of any component of this pathway, such as overexpression of cyclin D related CDKs, or mutations to CDKs that affect p16 binding, will lead to Rb phosphorylation and subsequent progression from G1 to S phase[31,32].”
BackgroundRetractedImpaired inhibition of NF-κB activity by melanoma-associated p16INK4a mutations
Becker, T. M., Rizos, H., Peña, A., Leclercq, I. A., Woodruff, S., Kefford, R. F., & Mann, G. J. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.032 · Cited by 18
“Furthermore, the importance of this pathway in melanoma predisposition is evident as three melanoma-prone families carry a germline mutation in CDK4, which prevents kinase inhibition by p16INK4a [6].”
BackgroundGenetic susceptibility to cutaneous melanoma in southern Switzerland: role ofCDKN2A,MC1RandMITF
Mangas, C., Potrony, M., Mainetti, C., Bianchi, E., Carrozza-Merlani, P., Eberhardt, A. M., Maspoli-Postizzi, E., Marazza, G., Marcollo-Pini, A., Pelloni, F., et al. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14897 · Cited by 17
Harris, A. L., Lee, S. E., Dawson, L. K., Marlow, L. A., Edenfield, B. H., Durham, W. F., Flotte, T. J., Thompson, M. A., Small, D. L., Synnott, A. J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23649 · Cited by 18
“Mechanisms that cause CDK4/6-Rb pathway dysregulation include amplifications in cyclin D1 [28] and activating mutations in CDK4 [29].”
BackgroundMacias, E., de Marval, P. L. M., Siervi, A. D., Conti, C. J., Senderowicz, A. M., & Rodríguez‐Puebla, M. L. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.071124 · Cited by 18
Cazenave, H., Maubec, E., Mohamdi, H., Grange, F., Paillerets, B. B., Démenais, F., & Avril, M.-F. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12421 · Cited by 20
Integrated case-control and somatic-germline interaction analyses of melanoma susceptibility genes
Yu, Y., Hu, H., Chen, J., Hu, F., Fowler, J., Scheet, P. A., Zhao, H., & Huff, C. D. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.01.007 · Cited by 16
“Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, Hayward N, Dracopoli NC, Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma, Nature genetics, 12 (1996) 97–99.”
BackgroundRecent advances in melanoma research via “omics” platforms
Rodríguez‐Cerdeira, C., Molares-Vila, A., Carnero-Gregorio, M., & Corbalán-Rivas, A. (2017) · Journal of Proteomics · doi:10.1016/j.jprot.2017.11.005 · Cited by 16
Birkeälv, S., Harland, M., Matsuyama, L. S. A. S., Rashid, M., Mehta, I., Laye, J. P., Haase, K., Mell, T., Iyer, V., Robles‐Espinoza, C. D., et al. (2022) · The Journal of Pathology · doi:10.1002/path.6019 · Cited by 17
Hedaoo, A., Khairnar, P., Vambhurkar, G. B., Srinivasarao, D. A., Negi, M., Shinde, A., & Srivastava, S. (2024) · European Polymer Journal · doi:10.1016/j.eurpolymj.2024.113282 · Cited by 16
Cooperation of DLC1 and CDK6 Affects Breast Cancer Clinical Outcome
Dai, X., Li, L., Liu, X., Hu, W., Yang, Y., & Bai, Z. (2014) · G3 Genes Genomes Genetics · doi:10.1534/g3.114.014894 · Cited by 17
“…investigations have revealed that certain types of tumors selectively amplify either CDK4 or CDK6 (Wolfel et al. 1995; Timmermann et al. 1997; Zuo et al. 1996; Easton et al. 1998), and they have distinct subcellular localization (Grossel et al. 1999; Ericson et al. 2003; Mahony et al. 1998;…”
Lang, J., Shennan, M. G., Njauw, J. C.-N., Luo, S., Newton‐Bishop, J., Harland, M., Hayward, N. K., Tucker, M. A., Goldstein, A. M., Landi, M. T., et al. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.331 · Cited by 17
Self-citationLang, J., Hayward, N. K., Goldgar, D. E., Tsao, H., Hogg, D., Palmer, J. M., Stark, M. S., Tobias, E. S., & MacKie, R. M. (2006) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20410 · Cited by 16
“Genetic analysis of these melanoma families demonstrates germline mutations of CDKN2A (MIM no. 600,160) (Kamb et al., 1994; Nobori et al., 1994) in 20–30% of patients (Hussussian et al., 1994; Dracopoli and Fountain, 1996; Zuo et al., 1996; Harland et al., 1997).”
BackgroundSelf-citationThe P48T germline mutation and polymorphism in the CDKN2A gene of patients with melanoma
Huber, J., & Ramos, E. S. (2006) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2006000200010 · Cited by 16
“A single nucleotide polymorphism in the 3' untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare.”
BackgroundInfluentialChalony, C. L., Renard, C., Vincent-Naulleau, S. S., Créchet, F., Leplat, J. J. J. J., Tricaud, Y., Horák, V., Gruand, J., Roy, P. L., Frelat, G., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10871 · Cited by 16
Wurm, E. M. T., Lin, L. L., Ferguson, B., Lambie, D., Prow, T. W., Walker, G. J., & Soyer, H. P. (2012) · Experimental Dermatology · doi:10.1111/j.1600-0625.2012.01543.x · Cited by 15
Self-citationLevin, T., & Mæhle, L. (2016) · Familial Cancer · doi:10.1007/s10689-016-9939-8 · Cited by 16
Glutamatergic Signaling a Therapeutic Vulnerability in Melanoma
Eddy, K., & Chen, S. (2021) · Cancers · doi:10.3390/cancers13153874 · Cited by 20
Wang, X., Sistrunk, C., & Rodríguez‐Puebla, M. L. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.11.032 · Cited by 17
From Roscovitine to CYC202 to Seliciclib – from bench to bedside: discovery and development
Zhelev, N., Trifonov, D., Wang, S., Hassan, M., Serafi, I. E., & Mitev, V. (2013) · Biodiscovery · doi:10.7750/biodiscovery.2013.10.1 · Cited by 16
Novel germline CDK4 mutations in patients with head and neck cancer
Sabir, M., Baig, R. M., Mahjabeen, I., & Kayani, M. A. (2012) · Hereditary Cancer in Clinical Practice · doi:10.1186/1897-4287-10-11 · Cited by 19
“In vivo analysis of patients with the germ-line Arg24Cys mutation, revealed no documented changes in p16/CDKN2A binding site of CDK4 [29].”
BackgroundAdvances in cyclin-dependent kinase inhibitors for the treatment of melanoma
Julve, M., Clark, J. J., & Lythgoe, M. P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1828348 · Cited by 18
“This can occur through deletion or mutation of Rb [24], activating mutations in CDK4 [25,26] and CDK 6 [27], increased Cyclin D1 expression [21] or loss of p16INK4A (inhibitor”
BackgroundTargeted Therapies in Melanoma: Translational Research at Its Finest
Ho, A. W., & Tsao, H. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.14 · Cited by 15
“Given the genetic diversity of melanoma cells, there exist other attractive therapeutic targets including PI3K, CDK4, ERK, NF1, PPP6C, BCL-2, HSP90, mTOR, PDGF, Notch, MITF, and RAC1.”
InfluentialMelanoma in Childhood: Review and Perspectives
Spatz, A., & Avril, M. (1998) · Pediatric and Developmental Pathology · doi:10.1007/s100249900064 · Cited by 15
Predisposición genética en el melanoma cutáneo
Avilés, J. A., & Lázaro, P. (2006) · Actas Dermo-Sifiliográficas · doi:10.1016/s0001-7310(06)73390-7 · Cited by 18
Towards a Better Understanding of the Molecular Mechanisms Involved in Sunlight‐Induced Melanoma
Williams, M., & Ouhtit, A. (2005) · BioMed Research International · doi:10.1155/jbb.2005.57 · Cited by 25
Hereditary cancer syndromes of the skin
Somoano, B., Niendorf, K. B., & Tsao, H. (2005) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2004.09.012 · Cited by 16
CDKN2 (MTS1/p16 INK4A ) Gene Alterations in Hematological Malignancies
Uchida, T., Kinoshita, T., Saito, H., & Hotta, T. (1997) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199709055583 · Cited by 18
Skin cancer and role of herbal medicines
Chauhan, P. (2018) · Asian Journal of Pharmacy and Pharmacology · doi:10.31024/ajpp.2018.4.4.5 · Cited by 17
Canonical Signaling Pathways in Melanoma
Sun, L., & Arbesman, J. (2021) · Clinics in Plastic Surgery · doi:10.1016/j.cps.2021.05.002 · Cited by 16
Henick, B. S., Taylor, A. M., Nakagawa, H., Wong, K., Diehl, J. A., & Rustgi, A. K. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.01.003 · Cited by 23
Potential Clinical Uses of CDK Inhibitors: Lessons from Synthetic Lethality Screens
Vymětalová, L., & Kryštof, V. (2015) · Medicinal Research Reviews · doi:10.1002/med.21354 · Cited by 14
New susceptibility loci for cutaneous melanoma risk and progression revealed using a porcine model
Bourneuf, E., Estellé, J., Blin, A., Créchet, F., Schneider, M. D. P., Gilbert, H., Brossard, M., Vaysse, A., Lathrop, M. G., Vincent-Naulleau, S. S., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25455 · Cited by 14
Chemical fragment-based CDK4/6 inhibitors prediction and web server
Wang, L., Li, Y., Xu, M., Pang, X., Liu, Z., Tan, W., & Xu, J. (2016) · RSC Advances · doi:10.1039/c5ra23289a · Cited by 16
Nadal, A., Jares, P., Pinyol, M., Conde, L., Romeu, C., Fernández, P. L., Campo, E., & Cardesa, A. (2006) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-006-0314-2 · Cited by 13
“A total of 0.5 μg of DNA was used as template in a standard PCR reaction containing PCR buffer, dNTPs 10 mM each, primers 1 mM each, 1 U of Taq DNA polymerase, and 5% DMSO in a reaction volume of 50 μl. Primers—modified from Zuo et al. [ 27 ]— were 5′-GCTGCAGGTCATACCATCCT-3′ (sense) and 5′-ATCACACCCCACCTATAGG-3′ (anti…”
BackgroundMethodInfluentialPolymorphisms in the syntaxin 17 gene are not associated with human cutaneous malignant melanoma
Zhao, Z., Duffy, D. L., Thomas, S. A., Martin, N. G., Hayward, N. K., & Montgomery, G. W. (2009) · Melanoma Research · doi:10.1097/cmr.0b013e328322fc45 · Cited by 14
Self-citationAdvances in malignant melanoma: genetic insights from mouse and man
Kabbarah, O., & Chin, L. (2006) · Frontiers in bioscience · doi:10.2741/1849 · Cited by 18
Jiao, W., Lin, H., Timmons, J. C., Nagaich, A. K., Ng, S., Misteli, T., & Rane, S. G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3999 · Cited by 14
“E2F1 (1-363) that retains the E2F1-specific retinoblastoma binding is as efficient in repression as WT E2F1 indicating that the E2F1-specific retinoblastoma-binding motif is sufficient for E2F1 repressor activity (Fig.”
BackgroundMethod
Metadata
- Authors
- Zuo, L., Weger, J., Yang, Q., Goldstein, A. M., Tucker, M. A., Walker, G. J., Hayward, N., & Dracopoli, N. C.
- Affiliations
- National Institutes of Health (US)
- QIMR Berghofer Medical Research Institute (AU)
- Venue
- Nature Genetics
- Published
- 1996-01
- Volume
- 12
- Issue
- 1
- Pages
- 97-99
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2051506850
- Cited by
- 818
- References
- 29
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 11 · 2023: 13 · 2022: 13 · 2021: 19 · 2020: 19 · 2019: 23 · 2018: 24 · 2017: 36 · 2016: 24 · 2015: 27 · 2014: 32 · 2013: 30 · 2012: 19
- FWCI
- 14.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- CDK4, germline mutations, familial melanoma, cyclin-dependent kinases, cyclin D, retinoblastoma protein phosphorylation, G1 cell cycle checkpoint, hereditary melanoma, tumor-specific antigens
- MeSH terms
- Base Sequence, Carrier Proteins, Female, Humans, Male, Melanoma, Molecular Sequence Data, Pedigree, Proto-Oncogene Proteins, DNA Primers, Polymorphism, Single-Stranded Conformational, Cyclin-Dependent Kinases, Cyclin-Dependent Kinase Inhibitor p16, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.